Phase II trial of trastuzumab (Herceptin), bevacizumab, and docetaxel (Taxotere) trial in stage IV metastatic breast cancer (MBC) patients

Trial Profile

Phase II trial of trastuzumab (Herceptin), bevacizumab, and docetaxel (Taxotere) trial in stage IV metastatic breast cancer (MBC) patients

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 May 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Docetaxel (Primary) ; Trastuzumab (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Jan 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Nov 2012, according to ClinicalTrials.gov record.
    • 29 Oct 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top